Cargando...
Overcoming mutation-based resistance to antiandrogens with rational drug design
The second-generation antiandrogen enzalutamide was recently approved for patients with castration-resistant prostate cancer. Despite its success, the duration of response is often limited. For previous antiandrogens, one mechanism of resistance is mutation of the androgen receptor (AR). To prospect...
Guardado en:
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
eLife Sciences Publications, Ltd
2013
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3622181/ https://ncbi.nlm.nih.gov/pubmed/23580326 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7554/eLife.00499 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|